Insulet PODD U.S.Omnipod — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's u.s.omnipod — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's u.s.omnipod — total revenue?
- Insulet (PODD) reported u.s.omnipod — total revenue of $515.6M in Q1 2026.
- How has Insulet's u.s.omnipod — total revenue changed year-over-year?
- Insulet's u.s.omnipod — total revenue increased by 28.4% year-over-year, from $401.7M to $515.6M.
- What is the long-term trend for Insulet's u.s.omnipod — total revenue?
- Over 4 years (2021 to 2025), Insulet's u.s.omnipod — total revenue has grown at a 31.0% compound annual growth rate (CAGR), from $651.5M to $1.92B.
- What does u.s.omnipod — total revenue mean?
- The total amount of money earned from selling the company's primary insulin delivery products in the United States.
- How do you interpret u.s.omnipod — total revenue?
- An increase indicates successful market penetration, higher patient adoption rates, or increased utilization of consumables, while a decrease may signal competitive pressure or saturation in the domestic diabetes management market.
- How does u.s.omnipod — total revenue compare across companies?
- Comparable to domestic product-line revenue metrics for other medical device manufacturers, particularly those in the chronic disease management or wearable health technology sectors.